Patient-centric R&D is imperative for pharma in delivering effective medicines and better outcomes. The push to implement it is challenging long-held biopharma business practices, including how clinical trials are designed, recruited and run – and what they measure.

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.